Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study

Table 1 Baseline characteristics of patients in the FILGUITO registry (n = 104)

Characteristic	Value
Demographics
Age (year)	40.7 (29.5-51.0)
Male sex	59 (56.7)
Disease duration (year)	11.1 (5.0-14.0)
Disease characteristics
Disease extent
Extensive colitis	54 (51.9)
Left-sided colitis	39 (37.5)
Proctitis	11 (10.6)
Smoking status
Never smoker	63 (60.6)
Former smoker	29 (27.9)
Current smoker	12 (11.5)
Extraintestinal manifestations	32 (30.8)
Laboratory parameters, mean (IQR)
C-reactive protein (mg/L)	3.4 (1.1-8.9); median 5 (2-16)
Fecal calprotectin (μg/g)	820 (450-1800); median 2000 (755.8-2392.5)
AST (U/L)	22 (18-30)
ALT (U/L)	24 (17-33)
Hemoglobin (g/dL)	13.1 (11.7-14.3)
Leukocytes (× 103/μL)	7.2 (5.8-9.8)
Neutrophils (× 103/μL)	4.8 (3.5-7.1)
Platelets (× 103/μL)	270 (230-310)

Data are presented as median (IQR) for continuous variables and n (%) for categorical variables. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.